1,889
Views
201
CrossRef citations to date
0
Altmetric
Original Article

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

, , &
Pages 2757-2765 | Accepted 23 Jul 2008, Published online: 19 Aug 2008
 

ABSTRACT

Objective: The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of rivaroxaban – a novel, oral, direct Factor Xa (FXa) inhibitor – in healthy elderly subjects.

Research design and methods: In this single-centre, single-blind, placebo-controlled, parallel-group, dose-escalation study, 48 subjects (aged 60–76 years) were randomized to receive a single oral dose of 30, 40 or 50 mg of rivaroxaban or placebo.

Results: Rivaroxaban was absorbed rapidly, reaching peak plasma concentration (Cmax) 4 h after dosing in all groups. Bioavailability, in terms of the area under the plasma concentration–time curve (AUC) and Cmax, increased slightly (less than dose proportionally) after administration of rivaroxaban 40 mg compared with 30 mg, but was not increased further with rivaroxaban 50 mg. Rivaroxaban pharmacodynamic effects (inhibition of FXa activity and prolongation of prothrombin time, activated partial thromboplastin time and HepTest) all showed a similar pattern, with maximum inhibition of FXa activity increasing from 68% after rivaroxaban 30 mg to 75% after 40 mg and no further increase with the 50 mg dose. Most adverse events were mild; observed rates were less than placebo for the 30 and 40 mg dose groups, and similar to placebo for 50 mg. No differences were found between male and female subjects. Effects of rivaroxaban doses above 50 mg were not investigated in this study.

Conclusions: Each single dose of rivaroxaban was well tolerated, with predictable pharmacokinetics and pharmacodynamics at doses up to 40 mg, and provided effective anticoagulation in healthy elderly subjects. Adverse events were somewhat elevated in the 50 mg group, but given the small sample size, no specific conclusions can be drawn about this dosing level.

Acknowledgements

This study was supported by Bayer HealthCare AG. All authors are employees of Bayer HealthCare AG. The authors wish to acknowledge Toby Allinson and Chris Thomas of Chameleon Communications, who provided medical writing assistance with funding from Bayer HealthCare.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.